

## 4<sup>th</sup> ILROG Educational Conference Faculty



**Professor George Mikhaeel**  
**Professor of Radiation Oncology, King's College London and**  
**Consultant Clinical Oncologist, Guy's and St Thomas' Cancer Centre**

George Mikhaeel is Professor of Radiation Oncology at King's College London University and Consultant Clinical Oncologist at Guy's & St Thomas' Cancer Centre, where he specialises in the treatment of lymphomas. His academic interest and research are focused on imaging and advanced radiotherapy techniques for lymphoma.

Professor Mikhaeel is a founding member of the International Lymphoma Radiation Oncology Group (ILROG) and a member of its steering committee. Nationally, he chairs the UK Lymphoma Radiotherapy Group (UK-LRG). He is co-author of several international guidelines in lymphoma and has lectured in more than 15 countries. He also chaired the haematology track for the American Society of Radiation Oncology (ASTRO) annual meeting scientific committee until 2020 and is currently a member of ASTRO education committee.



**Professor Tim Illidge**  
**Professor of Targeted Therapy and Oncology, University of Manchester and**  
**Honorary Consultant Clinical Oncologist, The Christie NHS Foundation Trust**

Dr Illidge completed his undergraduate degrees with a BSc in Biochemistry (London) and medicine (MB BS) at Guy's Hospital, Royal College of Physicians (1993) and trained in clinical oncology in Southampton gaining Fellow of Royal College of Radiologists in 1997. In worked as CRUK Senior Clinical Research Fellow at University of Southampton 1998-2004 and was appointed Professor of Targeted Therapy and Oncology at University of Manchester in 2004. His awards have included cancer researcher of the year by University of Manchester in 2012, researcher of the year for the Faculty of Medical and Life sciences in 2013, the Royal College of Radiologists gold medal in 2018, Skeggs medal in 2019, a Senior National Institute of Health Research (NIHR) investigator award in 2019 and Fellow of the Academy of Medical Sciences in 2022.



**Professor Berthe Aleman**  
**Consultant Radiation Oncologist**  
**The Netherlands Cancer Institute, Amsterdam**

Berthe Aleman is a Radiation Oncologist at the Netherlands Cancer Institute in Amsterdam. Her clinical interests include lymphomas and gastrointestinal tumors. Her academic and research interests focus on lymphoma, late adverse effects of cancer treatment (for lymphoma and breast cancer) and survivorship.

She is the chair of the radiotherapy subcommittee of the EORTC lymphoma group and a member of the steering committee of the International Lymphoma Radiation Oncology Group (ILROG). Furthermore, she is one of the founding members of the consortium that developed and implemented a survivorship care program for adult lymphoma survivors in the Netherlands (so called BETER program).



**Dr Reuben Benjamin**  
**Consultant Haematologist**  
**King's College Hospital, London**

Dr Benjamin is a Clinical Senior Lecturer at King's College London and Consultant Haematologist at King's College Hospital with a specialist interest in multiple myeloma, stem cell transplantation and CAR T cell therapy. He leads the Plasma Cell Disorder Service and CAR-T cell programme at King's College Hospital, London and runs a research group focused on investigating mechanisms of resistance to CAR T cells, developing next generation CAR-T cells targeting cancer and autoimmune diseases as well as investigating the biology of multiple myeloma.



**Professor Louis S. Constine**  
**Professor of Radiation Oncology and Paediatrics**  
**University of Rochester Medical Center**

Louis S. Constine, MD, FASTRO, FACR is Professor of Radiation Oncology and Pediatrics and Vice Chair of the Department of Radiation Oncology. He was awarded fellowships in his professional society, The American Society of Radiation Oncology, in 2008, and in The American College of Radiology in 2018. After graduating from Stanford University, and The Johns Hopkins University School of Medicine, he trained in pediatrics, pediatric oncology and radiation oncology, and has board certification in these areas. His clinical and scientific expertise is in lymphomas, sarcomas, all pediatric malignancies, and the broad area of Survivorship that includes the acute and chronic effects of chemotherapy and radiation therapy on normal tissues.

He is the Director of the University of Rochester Medical Center (Judy DiMarzo) Survivorship Program, and the Radiation Chair of the Lymphoma Committee in the Southwest Oncology Group. He is on the core committees for the Children's Oncology Group Survivorship Guidelines, the International Survivorship Harmonization Guidelines, previously was on the American Society of Clinical Oncology Survivorship Advisory Group, and he leads the Pediatric Quantitative Analysis of Normal Tissue Effects in the Clinic ASTRO/AAPM initiative. He serves on the Children's Oncology Group Late Effects Steering Committee, is senior advisor for the COG Hodgkin Lymphoma Committee, and is on the executive committee of the Radiation Oncology Committee (leading an effort to compile normal tissue dose constraints for protocols). He has been an investigator on several grants including an ROI evaluating long-term cardiac toxicities in Hodgkin lymphoma survivors. He is a member of the steering committee for the NCI-supported Childhood Cancer Survivorship Study and am actively involved in select projects. He was a member of a four-person United Nations task force collating the adverse effects of radiation on children; he discussed their 240 page document at the UN international headquarters (Vienna) in 5/12 and again in 5/13 and it was internationally distributed. Other international efforts included his core membership on an International Atomic Energy Agency initiative to develop pediatric radiation oncology in low-income countries that met in Vienna in 6/13. Additional activities included membership on task forces for the American Heart Association on cardiotoxicity, and the National Council on Radiation Protection Scientific Committee on "Second Primary Cancers and Cardiovascular Disease after Radiation Therapy."

He is recipient of an NIH merit award in 2010, the Jacob Gitelman Award from Cancer Action, the "Make a Difference" Award from Melissa's Legacy, and the Teddy award from Camp Good Days and Special Times. He is included in the *America's Top Doctors for Cancer*. He is a member of numerous societies including The American Society of Radiation Oncology, the Radiation Research Society, the American Society of Clinical Oncology, and the American Society of Hematology. He has authored (co-authored) edited more than 50 book chapters (including the 6<sup>th</sup> edition of Pediatric Radiation Oncology- British Medical Book Award), edited eight books and ~250 original and invited reports.

His professional life is guided by his words: *For the survivor of cancer, the world is full and each day is a celebration - for the physician, each patient is an inspiration - for the person fighting cancer, each day is precious and must be faced with courage.*



**Professor Bouthaina Dabaja**  
**Professor and Section Chief of Radiation Oncology**  
**MD Anderson Cancer Center**

Dr Dabaja received her Medical Doctorate at the Lebanese University. She completed her clinical residencies at the American University of Beirut and The University of Texas MD Anderson Cancer Center. She began her career at MD Anderson following her residency in 2006 and has progressed from Assistant Professor to Professor and Section Chief of the Hematology Section in Radiation Oncology.

Her primary clinical goal is patient care with an emphasis on maintaining and improving cure rate in patients with lymphoma while decreasing the short and long term side effects of treatment. She is extensively involved in clinical trials to investigate multiple strategies to deliver better treatment options for lymphoma patients with the goal of minimizing long term side effects on patients treated for mediastinal lymphomas which remains a great clinical challenge.



**Professor Andrew Davies**  
**Professor of Haematological Oncology, Consultant in Medical Oncology**  
**Director Southampton Experimental Cancer Medicines Centre**  
**Chair UK National Cancer Institute Lymphoma Research Group**  
**Wessex Clinical Lead for Cancers in Teenagers and Young Adults**

Andrew Davies is Professor of Haematological Oncology in the Cancer Sciences Unit in the Faculty of Medicine, University Hospital Southampton. He completed his training in Medical Oncology at St Bartholomew's Hospital in London, and as a Cancer Research UK clinical fellow he undertook a PhD examining the molecular mechanisms underlying transformation of follicular lymphoma to more aggressive histological sub-types.

Prof Davies specialises in the treatment of malignant lymphoma. He has a particular interest in the investigation of monoclonal antibody-containing therapies and other novel therapeutics applied to lymphoma. His work also focuses on translation of biomarkers and novel therapies to the clinical arena. He has extensive experience in early phase trials, including leading several first in man lymphoma studies all the way through to leading late phase studies.

He is Chair of the UK National Cancer Research Institute Lymphoma Research Groups and past Chair of the High Grade Lymphoma Study Group. He is Director of the Cancer Research UK/National Institute of Health Southampton Experimental Cancer Medicine Centre. He is also the Wessex regional lead for cancers in Teenagers and Young Adults (TYA) and Clinical Lead for the Thames Valley and Wessex TYA Operational Delivery Network.




**Professor Hans Eich**  
**Professor of Radiation Oncology**  
**University of Münster**

Hans Theodor Eich, MD, PhD, has served as the chair of the Münster University Radiation Oncology Department in Münster, Germany, since 2011. Having completed his residency on Essen and Cologne, he has helped shape the German Hodgkin Study Group (GHSg) HD trial series on the use of radiotherapy in Hodgkin lymphoma. As a professor in radiation oncology, he currently serves as the chair of the GHSg radiotherapy panel, chair of the Radiotherapy Group within the Germany Lymphoma Alliance (GLA) and a member of the International Lymphoma Radiation Oncology Group (ILROG) steering committee. His research interests include dose de-escalation in Hodgkin and low grade non-Hodgkin lymphoma as well as image-guided target volume definition.



**Professor David Hodgson**  
**Professor of Radiation Oncology**  
**Princess Margaret Cancer Centre, Toronto**

David Hodgson is a Professor in the Department of Radiation Oncology, and the Institute for Health Policy, Management and Evaluation, University of Toronto. He is the Medical Director of the Pediatric Oncology Group of Ontario (POGO), and holds the POGO Chair in Childhood Cancer Control at the University of Toronto. In addition to practicing radiation oncology in the lymphoma and pediatric site groups at the Princess Margaret Cancer Centre, Dr Hodgson serves on the Hodgkin Lymphoma Steering Committee of the Children's Oncology Group.



**Professor Richard Hoppe**  
**Professor in Cancer Biology and Radiation Oncology**  
**Stanford University, California**

Richard T. Hoppe, MD, FACR, FASTRO, FARS is the Henry S. Kaplan-Harry Lebeson Professor of Cancer Biology and Radiation Oncology at Stanford University. He served as Chair of the Department of Radiation Oncology for 19 years. His research interests include the lymphomas, radiation immunosuppression, and radiation late effects. He is Chair of the Hodgkin Lymphoma and member of the T-Cell and Cutaneous Lymphoma Guideline Panels for the National Cancer Center Network (NCCN). He is on the Steering Committee of the International Lymphoma Radiation Oncology Group (ILROG). He has received the Gold Medals of the American Society for Radiation Oncology (ASTRO), the American College of Radiology (ACR) and the American Radium Society (ARS). He is a recipient of the Karl Musshoff Prize for Clinical Research from the German Hodgkin Lymphoma Study Group, a Lifetime Achievement Award from the International Society for Cutaneous Lymphoma (ISCL), and the Albion Walter Hewlett Award from the Department of Medicine at Stanford.



**Dr Brandon Imber**  
**Assistant Attending Radiation Oncologist**  
**Memorial Sloan Kettering Cancer Centre**

Brandon Imber, MD, MA, is an assistant attending radiation oncologist at Memorial Sloan Kettering Cancer Center. His clinical and research expertise is treating hematologic malignancies and central nervous system cancers. Dr. Imber also serves as the Director of Research for the Hematologic Radiation Oncology Service at MSKCC and serves as one of the Council Members for the International Lymphoma Radiation Oncology Group (ILROG). Dr Imber earned his medical degree at University of California San Francisco (UCSF) School of Medicine and did his residency at Memorial Sloan Kettering where he served as Chief Resident. He also completed a clinical and research fellowship in hematologic radiation oncology. His research interests span multiple topics in the hematologic malignancies including combining radiotherapy with novel cellular and immunotherapies, study of sublethal dose radiotherapy for treatment of indolent lymphomas and modern utilization of radiotherapy for CNS lymphomas.




**Dr Anne Kiil Berthelsen**  
**Chief Physician, Oncology**  
**Ringshospitalet, University of Copenhagen**

MD from University of Copenhagen. Registered specialist in Radiology, National Board of Health, Denmark.

Steering Committee member, ILROG. Active member of the Danish Radiology Society, Danish Lymphoma Group, and Danish Society for Magnetic Resonance Imaging.

Primary areas of interest: Imaging, contouring, and radiation therapy planning in hematological malignancies, head & neck cancer, and gynecological malignancies. Co-supervisor of PhD theses and postdoctoral projects.

Publications: > 220 scientific publications and book chapters.



**Professor Youlia M. Kirova**  
**Senior Radiation Oncologist and Associate Professor of Radiation Oncology**  
**Institut Curie**

Professor Youlia M. Kirova, MD is a Senior Radiation Oncologist and Associate Professor in the Department of Radiation Oncology of the Institut Curie, Paris, France. Involved in patients' care (breast cancer and haematological malignancies) as well as in the clinical and translational research, she participates in the development of new treatment protocols, new radiotherapy techniques. Expert in the NCI France (InCa) and the Cooperative Group of Radiation Oncologists UnitRad.


Youlia has an involvement in teaching nationally (SFRO, FROG, SFSMP) and internationally, as a teacher in the annual ESTRO EBRO (European Society of Therapeutic Radiology and Oncology) teaching course as well as ESO and ESSO. She is an active member of the Steering Committee ILROG (International Lymphoma Radiation Oncology Group), as well as PTCOG Lymphoma Group, she is also Vice President of Breast PTCOG. She is a vice president of FROG (Francilian Onco Geriatric Group) and Member of International SIOG Radiotherapy Task Force, Member of SKAGEN Breast Cancer Group, Member of EORTC Breast, Radiation and Lymphomas Groups.

Prof Kirova was a visiting expert in Ruijin Hospital, Shanghai, China between 2016 and 2018. Since 2018: Visiting Professor in Harvard (DFCI, Brigham Hospital and MGH), USA, Department of Radiation Oncology (Breast Cancer and Hematological Malignancies). She is PI in different national and international phase I, II and III studies. She is involved in the translational work of the Institut Curie, Paris-Orsay. She authored and co-authored around 367 articles on Pub Med and several book chapters.



**Associate Professor Sarah Milgrom**  
**Associate Professor of Radiation Oncology**  
**University of Colorado**

Sarah Milgrom, MD, is an Associate Professor of Radiation Oncology. She completed her residency training at Memorial Sloan Kettering Cancer Center and was on the faculty at MD Anderson Cancer Center, before returning to her hometown of Denver to join the faculty at the University of Colorado. She specializes in the treatment of pediatric and hematologic malignancies. Her broad areas of scholarship include contributing to clinical guidelines and educational resources for the radiation oncology community, exploring the association of diagnostic imaging findings with oncologic outcomes, assessing the effects of radiation on normal tissues, and studying methods to improve the patient experience during radiation therapy.




**Professor Andrea Ng**  
**Professor of Radiation Oncology**  
**Dana-Farber Brigham Cancer Center, Harvard Medical School**

Andrea K. Ng, MD, MPH, is Professor of Radiation Oncology, BWH Distinguished Chair in Clinical Radiation Oncology, Vice-chair of Faculty Promotion and Advancement, and Director of Hematologic Malignancy at the Department of Radiation Oncology at Dana-Farber Brigham Cancer Center, Harvard Medical School. Her clinical and academic focus is on the integration of novel radiation technique and dose-fractionation with modern systemic therapy to maximize the efficacy and minimize treatment-related toxicity for patients with hematologic malignancies.



**Associate Professor Chelsea Pinnix**  
**Associate Professor of Radiation Oncology**  
**MD Anderson Cancer Center**

Chelsea Pinnix is an Associate Professor in the Department of Radiation Oncology at MD Anderson Cancer Center where she specializes in the treatment of patients with hematologic malignancies. She graduated from the University of Pennsylvania School of Medicine in 2007, where she earned a medical degree and a PhD in Cell and Molecular Biology. She then completed residency MD Anderson Cancer Center in the Department of Radiation Oncology. In 2012 she joined MD Anderson as faculty on the Hematologic Malignancies section. Her research is focused on the maximization of the therapeutic ratio for patients with hematologic malignancies through the utilization of radiation therapy. She is the principal investigator of clinical studies aimed at decreasing normal tissue toxicity from radiation through the use of advanced technology to reduce radiation exposure, utilization of smaller field sizes or reduced RT doses. She is also focused on the identification of improved treatment strategies that incorporate radiation combined with immune based therapies in the management of aggressive and refractory lymphomas. She is presently the Director of the Radiation Oncology Residency Program at MD Anderson Cancer Center and the Vice-Chair of the MD Anderson Graduate Medical Education Committee. She is a board examiner for the ABR. She is the Co-PI of the MD Anderson Cancer Center NCTN LAPS UG1 grant. She currently acts as the Education Council Vice-Chair on the Board of Directors for the American Society for Radiation Oncology (ASTRO), she serves as the Radiation Oncology Chair on the SWOG Myeloma committee as well as the Radiation Oncology Representative on the NCI Lymphoma Steering Committee.



**Professor John Plastaras**  
**Professor of Radiation Oncology, Hospital of the University of Pennsylvania**

John Plastaras, MD, PhD is a Professor in the Department of Radiation Oncology at Penn Medicine. His research program has focused on the use of proton therapy for gastrointestinal and hematologic malignancies as well as the combination of immune therapies and radiation for lymphomas. He was the principal investigator for a multi-site trial using proton therapy for re-irradiation and has organized a multi-center effort around the use of radiation bridging for CAR T-cell therapy. He served in leadership positions on the Hematologic Track Scientific Committee for the Annual meeting of the American Society for Radiation Oncology (ASTRO). He has been the Chair of the Education Committee and a member of the Steering Committee of the International Lymphoma Radiation Oncology Group (ILROG). At Penn Medicine Radiation Oncology, he is the Chief of the Gastrointestinal and Hematologic Malignancies Service and is the Vice Chair for Strategic Clinical Research. He serves as the co-Chair of the Abramson Cancer Center's Scientific Protocol Review Committee. He has been a chair of one of the Institutional Review Boards at the University of Pennsylvania that focused on cellular therapies and high risk cancer trials for several years. He is interested in promoting the use of radiotherapy in hematologic malignancies in cooperative group trials. With that goal in mind, he joined the recently formed NRG Lymphoma Working Group as one of five members strategizing to ensure quality radiation in clinical trials across the NTCN.



**Dr Shunan Qi**  
**Associate Professor of Radiation Oncology**  
**Chinese Academy of Medical Sciences & Peking Union Medical College**

Dr Shunan Qi works as an attending physician in the Radiation Oncology Department of tumor hospital, CAMS and PUMC. She is a steering committee member of International Lymphoma Radiation Oncology Group (ILROG). She is also nominated as a council member for lymphoma group of China Anti-Cancer Association (CACA) since 2017. Dr Qi is an expert in extranodal NK/T cell lymphoma treatment, developed the modern radiation guidelines for this disease with the ILROG team. She's also a panel member of national lymphoma guideline in China.



**Professor Umberto Ricardi**  
**Professor of Radiation Oncology**  
**University of Turin**

Professor Ricardi is currently Full Professor and Chairman of Radiation Oncology at University of Turin, Italy. He is Dean of the School of Medicine at University of Turin. He is also serving as Director of the Department of Oncology at Health and Science Academic Hospital in Turin. Professor Ricardi's main areas of clinical and scientific interest include lymphoma, lung cancer and CNS tumors. He is also an expert in the development of cutting edge technologies in radiation oncology.

Professor Ricardi has authored more than 360 full research papers, and participated as an invited speaker in a number of national and international conferences. He is active in many educational activities, both at national and international level. He is a member of numerous scientific societies. He is a member of the Steering Committee of ILROG (International Lymphoma Radiation Oncology Group). He is former ESTRO (European Society for Radiotherapy and Oncology) President, serving from April 2018-April 2020.



**Professor Lena Specht**  
**Professor of Clinical Oncology, Consultant in Oncology**  
**Rigshospitalet, University of Copenhagen, Denmark**

Lena Specht is Professor of Clinical Oncology at the University of Copenhagen, Denmark, and Consultant at the Department of Oncology at Rigshospitalet, University of Copenhagen. Her main areas of research and clinical interest are lymphomas and head & neck cancer. She is author of over 350 research articles, educational papers and book chapters, including ILROG guidelines on radiation therapy for haematological malignancies and ESMO guidelines on peripheral T-cell lymphomas, cutaneous lymphomas, and CNS lymphomas. She has authored three textbooks. She has served on numerous national and international research evaluation committees, including Cancer Research UK, the Swiss Cancer League, the Swedish Research Council, and the Norwegian "National programme for clinical therapy research". She leads a Multidisciplinary Radiotherapy Research Group, comprising physicians, physicists, and civil engineers, and she has supervised 18 PhDs and numerous post doc, postgraduate, and pregraduate projects. She is Editor of the Cochrane Haematological Malignancies Group and member of the Advisory Board for Acta Oncologica. She is Chairman of the Danish Lymphoma Radiation Oncology Group and the Radiotherapy Committee of the Danish Lymphoma Group, and past Chairman of the Danish Hodgkin Lymphoma Group, and she is Vice President of the International Lymphoma Radiation Oncology Group (ILROG). She has given > 200 invited international research and teaching lectures worldwide, and she is Course Director for the ESTRO-ILROG School Course on Haematological Malignancies. She received the Prize of the Danish Society of Oncology ("Onkologi-prisen") in 2004, and the ESTRO (European Society for Radiotherapy and Oncology) Lifetime Achievement Award in 2022.



**Professor Richard Tsang**  
**Radiation Oncologist, Princess Margaret Cancer Centre and**  
**Professor of Radiation Oncology, University of Toronto**

Richard W. Tsang, MD, is a Staff Radiation Oncologist at the Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. He has been active staff since 1990.

He is also Professor at the Department of Radiation Oncology, University of Toronto.

His clinical and research interests are in hematological malignancies (including lymphomas, plasma cell diseases), and advanced imaging techniques and precision radiation therapy. He had served as the Lymphoma Site Group Leader in the Radiation Medicine Program at Princess Margaret Cancer Centre.



**Associate Professor Yolanda Tseng**  
**Associate Professor of Radiation Oncology, University of Washington and**  
**Joint Associate Professor, Fred Hutchinson Cancer Center**


Yolanda Tseng, MD, MPhil currently serves as an Associate Professor in the Department of Radiation Oncology, University of Washington and a Joint Associate Professor at the Fred Hutch Cancer Research Center (Seattle, WA). Her clinical interests are in hematological malignancies, primary CNS tumors, and palliative radiotherapy. Her academic interests are centered on questions that inform therapeutic decisions in daily clinical practice. These include 1) using advanced treatment techniques and treatment algorithms to widen the therapeutic ratio for late effects in lymphoma patients, 2) evaluating how patient characteristics and tumor subtypes affect responses to radiotherapy, and 3) understanding clinical decision-making and workflows in palliative radiotherapy and use of radiation at the end of life.

She currently serves as Chair of the Proton Collaborative Group (PCG) lymphoma committee, co-chair of the Particle Therapy Co-Operative Group (PTCOG) lymphoma subcommittee, Chair of the ASTRO annual scientific committee Palliative track, council member for the International Lymphoma Research Oncology Group (ILROG), and on the executive committee for Society for Palliative Radiation Oncology.



**Associate Professor Andrew Wirth**  
**Radiation Oncologist**  
**Peter MacCallum Cancer Centre**

Associate Professor Andrew Wirth graduated in medicine at the University of Melbourne in 1981 and after completing training in medical and radiation oncology, was appointed consultant radiation oncologist at the Peter MacCallum Cancer Centre. He completed his MD Thesis on “The role of radiotherapy and imaging in the management of haematological malignancies” through the University of Melbourne in 2009. His areas of clinical expertise include the management of haematological, thoracic and CNS malignancies. His research has focused on radiotherapy for initial and salvage therapy for a range of lymphomas and the use of PET scanning for staging and response assessment in lymphomas. He has been lead investigator on several national clinical trials through the Australasian Leukemia Lymphoma Group and the Trans-Tasman Radiation Oncology Group, as well as lead investigator on an International Extra-nodal Lymphoma Study Group study. He is on the editorial board of Leukemia and Lymphoma, a has been a member of the UICC TNM Expert Advisory Panel on Lymphoma and on the scientific advisory committee for aggressive lymphomas of the Australasian Leukemia and Lymphoma Group. He has served on State and National guidelines committees for lymphoma. He is a founding member of the International Lymphoma Radiation Oncology Group and has been involved in several key guideline publications on involved-site radiotherapy. He led the radiation oncology section of the haematology service at the Peter MacCallum Cancer Centre and the Box Hill Campus for over 20 years.



**Professor Joachim Yahalom**  
**Professor of Radiation Oncology**  
**Memorial Sloan-Kettering Cancer Center**

Dr Joachim Yahalom is the founder and Chairman of the International Radiation Oncology Group (ILROG). He is Member and Professor of Radiation Oncology at Memorial Sloan-Kettering Cancer Center and Cornell University, respectively. Following training at the Hebrew University of Jerusalem, he joined the faculty of MSKCC where he leads the Radiation Hematology team and co-chairs the Lymphoma Disease Management Team. Dr Yahalom has led development of recent ILROG guidelines for hematological malignancies which have established modern standard of care. His research focuses on the integration of radiotherapy into the management of hematological malignancies. Among his contributions: incorporation of RT into salvage programs of lymphoma, establishing RT as a curative approach for MALT lymphomas, combined modality treatment of primary CNS lymphomas. Other research included autophagy as a radiation-induced death mechanism and currently, molecular signature to distinguish radiation responsiveness of follicular lymphomas. Potential radiation-induced enhancement of immunotherapies, particularly CAR-T cells is a current research focus of his group.